Immatics (NASDAQ: IMTX) — Perfil da empresa, notícias e dados financeiros
Immatics is a biopharmaceutical company developing T-cell receptor-based immunotherapies to significantly improve cancer patient outcomes.
Immatics
Immatics (NASDAQ:IMTX) focuses on the discovery and development of T-cell receptor-based immunotherapies for the treatment of cancer. This biopharmaceutical company is at the forefront of creating innovative approaches for targeting and combating cancer, leveraging its deep understanding of cancer immunology to develop therapies that aim to improve patient outcomes significantly. Immatics' operations encompass a broad range of projects, from early-stage research to clinical development, with the objective of advancing its pipeline of adoptive cell therapies, bispecific molecules, and antibody-like molecules designed to effectively target and eliminate cancer cells. Through its dedication to innovation and collaboration, Immatics strives to unleash the full potential of the immune system's ability to fight cancer.
Resumo
Operações
Produtos e/ou serviços de Immatics
- ACTolog IMA101, a personalized TCR-T therapy targeting multiple neoantigens for solid tumors.
- IMA202, a TCR-T therapy targeting MAGE-A4 positive tumors in various cancers.
- IMA203, targeting PRAME-specific T cells for solid tumors.
- Bispecific TCR molecules, aimed at dual-targeting of cancer cells for improved efficacy.
- Adoptive cell therapies using engineered T cell receptors (TCRs) for precision immunotherapy.
- Target discovery platform, utilizing XPRESIDENT technology for identifying novel cancer targets.
equipe executiva do Immatics
- Harpreet SinghCEO, MD, Member of Management Board & Executive Director
- Venkat RamananChief Financial Officer
- Amie KrauseChief People Officer
- Hans-Georg RammenseeCo-Founder & Member of the Scientific Advisory Board
- Toni WeinschenkCo-Founder & Chief Innovation Officer
- Steffen WalterChief Operations Officer
- Ephraim HofsäßVice President of SEC Reporting & Accounting
- James PepinGeneral Counsel & Corporate Secretary
- Lauren SchroederVice President of Marketing
- Carsten ReinhardtChief Development Officer
Últimas notícias sobre a Immatics
Principais indicadores financeiros
Resultados divulgados pela Immatics , em EUR.
- Cap. de mercado
- 1,1 bi
- Receita (TTM)
- 41,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.9
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 48,3 mi | -182 mi | -196,4 mi | |
| 155,8 mi | -38,6 mi | 15,2 mi | |
| 54 mi | -101,7 mi | -94,6 mi | |
| 172,8 mi | 30 mi | 27,7 mi |